Current status of pelvic lymph node dissection in prostate cancer

Area of Science:

• Urology
• Oncology
• Surgical Oncology

Background:

• Pelvic lymph node dissection (PLND) is the standard for detecting lymph node invasion in prostate cancer (PCa).
• Debate exists regarding the optimal extent of PLND and its therapeutic value in PCa management.
• Current consensus suggests extended PLND (ePLND) for specific PCa patient groups undergoing radical prostatectomy.

Purpose of the Study:

• To review the debate surrounding limited versus extended PLND in prostate cancer patients.
• To discuss the diagnostic and therapeutic potential of ePLND.
• To examine the role of robotic-assisted surgery in performing PLND.

Main Methods:

• Literature review of studies comparing limited and extended PLND.
• Analysis of outcomes, including oncological results and complication rates.
• Evaluation of robotic-assisted surgery's utility in PLND.

Main Results:

• Promising results suggest both diagnostic and therapeutic benefits of ePLND.
• Robotic-assisted surgery demonstrates comparable oncological outcomes and complication rates to traditional PLND.
• Criticisms persist regarding increased complications, hospitalization, and costs associated with more aggressive dissection.

Conclusions:

• Extended PLND offers potential benefits for prostate cancer staging and treatment.
• Further prospective, multi-center, long-term studies are essential to validate ePLND's efficacy and safety.
• Addressing concerns about risks and costs is crucial for widespread adoption of ePLND.